ProfessorDavid Klug
Associate Dean for Enterprise for FoNS & Professor
Department of Chemistry - Faculty of Natural Sciences
Orcid identifier0000-0001-9301-1654 (opens in a new tab)
- Associate Dean for Enterprise for FoNS & ProfessorDepartment of Chemistry - Faculty of Natural Sciences
- 020 7594 5806 (Work)
- Molecular Sciences Research Hub, White City Campus, United Kingdom
BIO
David Klug is Professor of Chemical Biophysics, reflecting his interests in multidisciplinary research and novel ways of working. He joined the Department of Chemistry in October 1998, having from October 1995 held a joint position in the Departments of Biochemistry and Chemistry. From October 1990 to September 1995 he was a Royal Society University Research Fellow jointly in Biochemistry and Chemistry. He graduated in Physics at University College London in 1984, and obtained his Ph.D. at The Royal Institution in 1987.
David is co-founder of the Institute of Chemical Biology (www.chemicalbiology.ac.uk ), which co-ordinates teaching and research activities in Chemical Biology. He also chaired the Single Cell Proteomics Project, a £5 million multidisciplinary collaboration of eight research teams developing and applying novel platform technologies to high throughput and single cell analysis and the Proxomics Project, platform technologies for the analysis of oxidative damage to proteins.
Current research interests are focused on the development and deployment of two platform technologies. 1) EVV 2DIR spectroscopy for the analysis of drug-target binding contacts and geometry. 2) Single molecule-sensitive affinity assays for the analysis of single and rare human primary cells in a variety of contexts.
David is currently Associate Dean for Enterprise and works with Imperial College start-ups and strategic partners. He assists with bringing Imperial College inventions to the wider world for socio-economic benefit.
David is also Chief Scientific Officer of Panacea Diagnostics, a company dedicated to the development of a universal platform for monitoring health and the early detection of disease.
David is co-founder of the Institute of Chemical Biology (www.chemicalbiology.ac.uk ), which co-ordinates teaching and research activities in Chemical Biology. He also chaired the Single Cell Proteomics Project, a £5 million multidisciplinary collaboration of eight research teams developing and applying novel platform technologies to high throughput and single cell analysis and the Proxomics Project, platform technologies for the analysis of oxidative damage to proteins.
Current research interests are focused on the development and deployment of two platform technologies. 1) EVV 2DIR spectroscopy for the analysis of drug-target binding contacts and geometry. 2) Single molecule-sensitive affinity assays for the analysis of single and rare human primary cells in a variety of contexts.
David is currently Associate Dean for Enterprise and works with Imperial College start-ups and strategic partners. He assists with bringing Imperial College inventions to the wider world for socio-economic benefit.
David is also Chief Scientific Officer of Panacea Diagnostics, a company dedicated to the development of a universal platform for monitoring health and the early detection of disease.
FACULTY
- Faculty of Natural Sciences
POSITION NAME
- Associate Dean for Enterprise for FoNS & Professor